In this Annual Report, we have disclosed forward-looking information to enable investors to comprehend our prospects and take investment decisions. This report and our other statements- written and oral- that we periodically make contain forward looking statements that set out anticipated results based on the management plans and the assumptions. We have tried wherever possible to identify such statements by using words such as "anticipate", "estimate", "expects", "projects", "intends", "plans", "believes" and words of similar substance in connection with any decision of future performance. We cannot guarantee that these forward-looking statements will be realised, although we believe we have been prudent in assumptions. The achievements of results are subject to risks, uncertainities and even inaccurate assumptions. Should known or unknown risks or uncertainities materialise or should underlying assumptions prove inaccurate, actual results could vary materially from those anticipated, estimated or projected. Readers should keep this in mind. We undertake no obligation to publicly update any forward-looking statements, where as a result of new information, future events or otherwise.
Vision
Become a composite and
meaning fully integrated pharmaceutical corporation
competing in differentiated arenas where greater, more sustainable value can be created
Corporate Information
Board of Directors
Shri Ram Gopal Agarwal, Chairman & Non-Executive Director
Shri Manish Dhanuka, Managing Director
Shri Mridul Dhanuka, Whole-timeDirector
Smt Tanu Singla, Independent Director
Dr Dharam Vir, Independent Director
Shri Mudit Tandon, Independent Director
Shri Manoj Kumar Goyal, Independent Director
Management Team
Shri Sunil Kumar Gupta, Chief Financial O®cer
Mr. Antony Martin, Gm - Production - Non Sterile and Utilities
Mr. Satheesh Kumar, GM - Sterile, Production and Maintenance
Mr. Thirunavukkarasu R, General Manager - Quality Control
Mr. Chellapandi D, Senior General Manager - Engineering
Mr. S N Rajendiran, G M - Quality Assurance
Mr. Srinivasan S, Head - CTD & IPM
Dr R J Sarangdhar, Vice President - (Unit Head - API & FDF)
Ms. Marina Peter, Company Secretary & Compliance O cer
Orchid Pharma Ltd. published this content on 18 July 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 18 July 2023 09:14:08 UTC.
Orchid Pharma Limited is an India-based pharmaceutical company. The Company is engaged in the manufacturing of integrated active pharmaceutical ingredients (API). It operates through the pharmaceutical segment. It has a multi-therapeutic presence across segments like anti-infectives, anti-inflammatory, central nervous system (CNS), cardiovascular segment (CVS), nutraceuticals and other oral and sterile products. Its pharmaceutical solutions include active pharmaceutical ingredients (APIs) and finished dosage forms. It offers APIs, including Cephalosporins-Orals, Cephalosporins-Injectables, Veterinary Products and Non-Antibodies. Its formulations include Cefixime Capsules, Acarbose Tablets, Acarbose Tablets, Clozapime Tablets, Clopidogrel Tablets, Desloratadine Tablets and Cefoperazone and Sulbactam for Injection, among others. Its subsidiaries include Orchid Europe Limited, Orchid Pharmaceuticals Inc., Bexel Pharmaceuticals Inc., and Diakron Pharmaceuticals, Inc., among others.
ORCHID PHARMA LIMITED 
